Observational studyBMC cancer2026

Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco.

Hassan Errihani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.